Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices (Q37705374)

22 August 2017

1 reference

title

Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices (English)

1 reference

22 August 2017

1 reference

1

Ayalew Tefferi

1 reference

22 August 2017

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

51

1 reference

22 August 2017

4

1 reference

22 August 2017

576-582

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

Myelodysplastic Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003605313

10.3109/10428191003605313

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20214447